phrykt

Guardant Health, Inc. (GH): who owns it and who trades it

As of Nov 16, 2026, GH insiders reported 138 open-market sales worth $168M and 1 purchase worth $78.5K in the last 12 months, with 48% of the sale value made under pre-set 10b5-1 plans. The largest seller was AmirAli Talasaz (CEO), with $79M. 6 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Guardant Health

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and Congress mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns GH

592 funds and institutions reported GH shares worth $20.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 5.7%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.5.7%
T. Rowe Price Associates4.9%
Vanguard Capital Management LLC4.3%
FMR LLC (Fidelity)4.1%
Vanguard Portfolio Management LLC4.1%
Invesco Ltd.3.3%
Goldman Sachs Group Inc2.8%
Two Sigma Investments, LP2.8%
Capital International Investors2.6%
Deep Track Capital, LP2.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.7.62M5.75%$1.1B-34%
T. Rowe Price Associates6.51M4.91%$977M-7%
Vanguard Capital Management LLC5.76M4.34%$864M+2%
FMR LLC (Fidelity)5.49M4.14%$823M+33%
Vanguard Portfolio Management LLC5.45M4.11%$817M-7%
Invesco Ltd.4.43M3.34%$665M-10%
Goldman Sachs Group Inc3.78M2.85%$566M-15%
Two Sigma Investments, LP3.72M2.80%$558M-12%
Capital International Investors3.40M2.56%$510M-2%
Deep Track Capital, LP3.39M2.56%$509M+2%
Franklin Resources Inc3.24M2.44%$486M-6%
Ameriprise Financial Inc3.15M2.38%$473M+123%
Fuller & Thaler Asset Management, Inc.2.63M1.98%$394M+3%
Geode Capital Management, LLC2.52M1.90%$378M-28%
Baillie Gifford & Co2.28M1.72%$343M-41%
State Street Corp2.26M1.71%$340M-22%
Federated Hermes, Inc.2.00M1.51%$300M+6%
Eventide Asset Management, LLC1.96M1.48%$294M-17%
Lord, Abbett & Co. LLC1.81M1.37%$272M-5%
Jane Street Group, LLC1.78M1.34%$268M–

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, GH insiders reported $78.5K of open-market purchases and $168M of sales. 48% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$78.5K
1 trades, 1 people
Sales, 12 months
$168M
138 trades, 15 people
Sales under a 10b5-1 plan
48%
Share of sale value
Latest trade
Oct 16, 2026
Filed Oct 19, 2026

Purchases and sales by month

$56.4M$56.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 16, 2026Musa TariqDirectorSale plan116$165.88$19.2KForm 4
Oct 14, 2026Alex M Azar IIDirectorSale plan69$159.89$11KForm 4
Sep 16, 2026Steve E. KrognesDirectorSale1,103$174.46$192KForm 4
Sep 16, 2026Steve E. KrognesDirectorSale971$177.48$172KForm 4
Sep 16, 2026Steve E. KrognesDirectorSale1,300$176.34$229KForm 4
Sep 16, 2026Steve E. KrognesDirectorSale3,300$175.42$579KForm 4
Sep 16, 2026Alex M Azar IIDirectorSale plan826$175.00$145KForm 4
Sep 16, 2026Musa TariqDirectorSale plan116$175.00$20.3KForm 4
Sep 15, 2026Darya ChudovaChief Technology OfficerSale7,738$178.00$1.4MForm 4
Sep 11, 2026Kumud KaliaChief Information OfficeSale4,000$158.05$632KForm 4
Aug 21, 2026AmirAli TalasazCEOSale20,888$169.16$3.5MForm 4
Aug 21, 2026AmirAli TalasazCEOSale9,023$168.20$1.5MForm 4
Aug 21, 2026AmirAli TalasazCEOSale7,589$170.29$1.3MForm 4
Aug 17, 2026Musa TariqDirectorSale plan116$156.45$18.1KForm 4
Aug 12, 2026Terilyn J. MonroeChief People OfficerSale400$167.92$67.2KForm 4
Aug 12, 2026Terilyn J. MonroeChief People OfficerSale13,248$166.11$2.2MForm 4
Aug 12, 2026Terilyn J. MonroeChief People OfficerSale19,014$165.16$3.1MForm 4
Aug 12, 2026Terilyn J. MonroeChief People OfficerSale9,934$164.27$1.6MForm 4
Aug 12, 2026Terilyn J. MonroeChief People OfficerSale3,704$163.41$605KForm 4
Aug 10, 2026Chris FreemanChief Commercial OfficerSale35,364$169.63$6MForm 4
Aug 10, 2026Chris FreemanChief Commercial OfficerSale7,365$168.79$1.2MForm 4
Aug 10, 2026Chris FreemanChief Commercial OfficerSale3,463$167.38$580KForm 4
Aug 10, 2026Chris FreemanChief Commercial OfficerSale17,413$170.24$3MForm 4
Aug 5, 2026Medina Manuel HidalgoDirectorSale950$163.95$156KForm 4
Aug 5, 2026Medina Manuel HidalgoDirectorSale750$164.61$123KForm 4
Aug 4, 2026Ian T ClarkDirectorSale9,088$158.98$1.4MForm 4
Aug 4, 2026Ian T ClarkDirectorSale5,092$158.80$809KForm 4
Jul 16, 2026Musa TariqDirectorSale plan116$163.29$18.9KForm 4
Jun 29, 2026AmirAli TalasazCEOSale plan46,663$152.20$7.1MForm 4
Jun 29, 2026AmirAli TalasazCEOSale plan40$153.00$6.1KForm 4
Jun 29, 2026AmirAli TalasazCEOSale plan25,812$150.53$3.9MForm 4
Jun 29, 2026AmirAli TalasazCEOSale plan70,513$151.47$10.7MForm 4
Jun 26, 2026AmirAli TalasazCEOSale plan52,935$151.16$8MForm 4
Jun 26, 2026AmirAli TalasazCEOSale plan64,037$150.49$9.6MForm 4
Jun 22, 2026Musa TariqDirectorSale plan1,951$131.16$256KForm 4
Jun 22, 2026Myrtle S PotterDirectorSale plan1,556$131.16$204KForm 4
Jun 16, 2026Musa TariqDirectorSale plan116$130.19$15.1KForm 4
Jun 15, 2026Kumud KaliaChief Information OfficeSale600$131.08$78.6KForm 4
Jun 15, 2026Kumud KaliaChief Information OfficePurchase600$130.76$78.5KForm 4
Jun 11, 2026Kumud KaliaChief Information OfficeSale3,418$130.24$445KForm 4
Jun 10, 2026Kumud KaliaChief Information OfficeSale600$130.86$78.5KForm 4
Jun 10, 2026Kumud KaliaChief Information OfficeSale5,000$130.41$652KForm 4
Jun 5, 2026Helmy EltoukhyCEOSale554$130.21$72.1KForm 4
Jun 5, 2026Helmy EltoukhyCEOSale900$131.78$119KForm 4
Jun 5, 2026Helmy EltoukhyCEOSale100$132.55$13.3KForm 4
Jun 5, 2026Helmy EltoukhyCEOSale13,787$128.25$1.8MForm 4
Jun 5, 2026Helmy EltoukhyCEOSale49,716$125.57$6.2MForm 4
Jun 5, 2026Helmy EltoukhyCEOSale1,100$127.02$140KForm 4
Jun 5, 2026Helmy EltoukhyCEOSale33,843$126.33$4.3MForm 4
Jun 5, 2026Michael Brian BellCFOSale2,000$128.62$257KForm 4
Jun 4, 2026Steve E. KrognesDirectorSale9,294$132.51$1.2MForm 4
Jun 3, 2026Meghan V. JoyceDirectorSale plan3,516$126.52$445KForm 4
Jun 3, 2026Meghan V. JoyceDirectorSale plan650$128.02$83.2KForm 4
Jun 3, 2026Meghan V. JoyceDirectorSale plan106$129.31$13.7KForm 4
Jun 3, 2026Meghan V. JoyceDirectorSale plan5,728$127.11$728KForm 4
May 28, 2026Medina Manuel HidalgoDirectorSale1,000$130.06$130KForm 4
May 27, 2026John G. SaiaChief Legal OfficerSale plan9,994$125.08$1.3MForm 4
May 27, 2026John G. SaiaChief Legal OfficerSale plan6$126.08$756Form 4
May 22, 2026Chris FreemanChief Commercial OfficerSale24,406$118.67$2.9MForm 4
May 20, 2026John G. SaiaChief Legal OfficerSale plan7,181$107.23$770KForm 4
May 20, 2026John G. SaiaChief Legal OfficerSale plan5,632$105.34$593KForm 4
May 20, 2026John G. SaiaChief Legal OfficerSale plan7,187$106.71$767KForm 4
May 20, 2026AmirAli TalasazCEOSale plan200$100.95$20.2KForm 4
May 20, 2026AmirAli TalasazCEOSale plan37,163$111.14$4.1MForm 4
May 20, 2026AmirAli TalasazCEOSale plan900$102.57$92.3KForm 4
May 20, 2026AmirAli TalasazCEOSale plan9,852$108.97$1.1MForm 4
May 20, 2026AmirAli TalasazCEOSale plan26,352$112.76$3MForm 4
May 20, 2026AmirAli TalasazCEOSale plan37,900$112.02$4.2MForm 4
May 20, 2026AmirAli TalasazCEOSale plan28,908$110.10$3.2MForm 4
May 20, 2026AmirAli TalasazCEOSale plan1,366$103.82$142KForm 4
May 20, 2026AmirAli TalasazCEOSale plan11,919$105.01$1.3MForm 4
May 20, 2026AmirAli TalasazCEOSale plan1,200$105.88$127KForm 4
May 20, 2026AmirAli TalasazCEOSale plan21,171$106.99$2.3MForm 4
May 20, 2026AmirAli TalasazCEOSale plan33,069$108.11$3.6MForm 4
May 20, 2026Ian T ClarkDirectorSale6,876$106.90$735KForm 4
May 20, 2026Medina Manuel HidalgoDirectorSale250$107.07$26.8KForm 4
May 20, 2026Medina Manuel HidalgoDirectorSale1,000$107.10$107KForm 4
May 18, 2026Musa TariqDirectorSale plan116$95.96$11.1KForm 4
May 12, 2026AmirAli TalasazCEOSale plan50,000$100.32$5MForm 4
Apr 16, 2026Musa TariqDirectorSale plan116$84.83$9.8KForm 4
Apr 6, 2026Terilyn J. MonroeChief People OfficerSale plan3,832$92.68$355KForm 4
Mar 18, 2026Musa TariqDirectorSale plan348$88.09$30.7KForm 4
Mar 16, 2026Michael Brian BellCFOSale3,000$87.04$261KForm 4
Mar 6, 2026Medina Manuel HidalgoDirectorSale300$91.30$27.4KForm 4
Mar 6, 2026Medina Manuel HidalgoDirectorSale1,000$91.61$91.6KForm 4
Mar 4, 2026Kumud KaliaChief Information OfficeSale13,020$95.73$1.2MForm 4
Mar 4, 2026Kumud KaliaChief Information OfficeSale26,980$95.12$2.6MForm 4
Jan 21, 2026Terilyn J. MonroeChief People OfficerSale plan1,703$112.34$191KForm 4
Jan 21, 2026Terilyn J. MonroeChief People OfficerSale plan3,249$115.70$376KForm 4
Jan 21, 2026Terilyn J. MonroeChief People OfficerSale plan3,619$113.48$411KForm 4
Jan 7, 2026Terilyn J. MonroeChief People OfficerSale plan88$113.44$10KForm 4
Jan 7, 2026Terilyn J. MonroeChief People OfficerSale plan3,632$112.62$409KForm 4
Jan 7, 2026Terilyn J. MonroeChief People OfficerSale plan6,311$111.75$705KForm 4
Dec 17, 2025Musa TariqDirectorSale plan116$101.46$11.8KForm 4
Dec 15, 2025Helmy EltoukhyCEOSale83,945$103.80$8.7MForm 4
Dec 15, 2025Helmy EltoukhyCEOSale6,620$104.02$689KForm 4
Dec 15, 2025Darya ChudovaChief Technology OfficerSale5,451$104.04$567KForm 4
Dec 8, 2025AmirAli TalasazCEOSale30,760$105.34$3.2MForm 4
Dec 8, 2025AmirAli TalasazCEOSale4,240$106.00$449KForm 4
Dec 8, 2025AmirAli TalasazCEOSale15,000$104.21$1.6MForm 4

Latest 100 of 139 trades in the last 12 months.

Insiders by value traded

InsiderRoleBoughtSoldLast trade
AmirAli TalasazCo-Chief Executive Officer, Director–$79MAug 21, 2026
Helmy EltoukhyCo-Chief Executive Officer, Director–$22MJun 5, 2026
Chris FreemanChief Commercial Officer–$16.9MAug 10, 2026
Terilyn J. MonroeChief People Officer–$15.9MAug 12, 2026
Michael Brian BellChief Financial Officer–$8.8MJun 5, 2026
Ian T ClarkDirector–$6.1MAug 4, 2026
Kumud KaliaChief Information Officer$78.5K$5.9MSep 11, 2026
Darya ChudovaChief Technology Officer–$4.4MSep 15, 2026
John G. SaiaChief Legal Officer–$3.4MMay 27, 2026
Steve E. KrognesDirector–$2.4MSep 16, 2026
Meghan V. JoyceDirector–$1.3MJun 3, 2026
Medina Manuel HidalgoDirector–$793KAug 5, 2026
Musa TariqDirector–$422KOct 16, 2026
Myrtle S PotterDirector–$204KJun 22, 2026
Alex M Azar IIDirector–$156KOct 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

GH short interest

Moderate short interest. 7.0% of GH shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went down 27%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.43M GH shares were sold short, 7.0% of the shares outstanding, down 19.2% from the report before. At the average daily volume of 1.75M shares, buying them all back would take about 5.4 trading days (days to cover).

Shares short, % of all shares

6.97%May 15Oct 3010.4%

Days to cover

5.4May 15Oct 307.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.43M6.97%-19%1.75M5.4
Oct 15, 202611.67M8.70%-2%1.75M6.7
Sep 30, 202611.92M8.88%+8%1.92M6.2
Sep 15, 202611.02M8.21%-0%1.67M6.6
Aug 31, 202611.05M8.23%-1%2.10M5.2
Aug 14, 202611.19M8.34%-2%1.95M5.7
Jul 31, 202611.42M8.51%No change2.12M5.4
Jul 15, 202611.42M8.61%-6%2.82M4.0
Jun 30, 202612.14M9.16%-7%4.25M2.9
Jun 15, 202613.09M9.87%-1%2.05M6.4
May 29, 202613.21M9.96%+2%2.93M4.5
May 15, 202612.93M9.75%+1%1.83M7.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded GH

Since Nov 17, 2024, 2 members of Congress reported 2 purchases and 0 sales of GH. The latest was a purchase by Jonathan L. Jackson on Sep 28, 2026, reported Oct 19, 2026.

Purchases 2Sales 0

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Sep 28, 2026Jonathan L. Jackson (D-IL)Purchase$15K–$50KJointOct 19, 2026Report
Nov 21, 2025Sheldon Whitehouse (D-RI)Purchase$1K–$15KSelfDec 1, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Guardant Health company events

Guardant Health filed 9 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Nov 3, 2026LeadershipThe Board of Directors of Guardant Health, Inc. increased the number of directors on the Board to 11 and appointed Kevin R. Sayer, 68, as a Class II director of the Company, to be effective as of November 2, 2026. Filing
  3. Nov 3, 2026LeadershipThe independent members of the Board of Directors of Guardant Health, Inc. approved the grant of performance-based restricted stock units under the Company’s 2018 Incentive Award Plan to each of the Company’s founders and Co-Chief Executive Officers, Helmy Eltoukhy and AmirAli Talasaz. Filing
  4. Jul 30, 2026ResultsReleased financial results. Filing
  5. Jun 18, 2026VoteReported shareholder vote results. Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Apr 27, 2026LeadershipGuardant Health, Inc. announced the resignation of Craig Eagle, M.D., the Company’s Chief Medical Officer, to be effective as of May 8, 2026. Filing
  8. Feb 19, 2026ResultsReleased financial results. Filing
  9. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Guardant Health financials

Famous investors that hold GH

6 of the 50 well-known investors we track reported holding GH in their latest 13F filing. The largest position is Ken Griffin's, worth $462M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20262.59M$462M0.3%+79%
Israel Englander · Millennium ManagementQ3 20261.12M$199M0.2%-31%
Steve Cohen · Point72 Asset ManagementQ3 2026637,905$114M0.2%-31%
Cathie Wood · ARK Investment ManagementQ3 2026607,173$108M0.6%+20%
Paul Tudor Jones · Tudor Investment CorpQ3 2026109,440$19.5M0.1%New
Ray Dalio · Bridgewater AssociatesQ3 20264,159$742K0.0%-2%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named GH in the last 120 days.

FiledHolderFormStake
Nov 5, 2026FMR LLC13G5.8%
Nov 5, 2026FMR LLC13G5.8%

Questions about Guardant Health, Inc. (GH) stock

Who owns the most GH stock?

The largest reported owner of Guardant Health, Inc. (GH) is BlackRock, Inc., with 5.7% of the company. In total, 592 funds and institutions reported holding GH at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are GH insiders buying or selling?

In the last 12 months, GH insiders reported 1 open-market purchase worth $78.5K and 138 sales worth $168M. The latest trade was on Oct 16, 2026. See every trade.

What is the short interest in GH?

As of Oct 30, 2026, 9.43M GH shares were sold short, 7.0% of the shares outstanding, down 19.2% from the report before. At the average daily volume of 1.75M shares, buying them all back would take about 5.4 trading days (days to cover). See the history.

Have members of Congress traded GH?

Yes. 2 members of Congress reported 2 purchases and 0 sales of GH since Nov 17, 2024. The latest was reported on Oct 19, 2026. See the trades.

Which famous investors hold GH?

6 of the 50 well-known investors we track reported GH in their latest 13F filing, including Ken Griffin, Israel Englander, Steve Cohen. The largest position is worth $462M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.